Connection

AMAN U BUZDAR to Survival Analysis

This is a "connection" page, showing publications AMAN U BUZDAR has written about Survival Analysis.
Connection Strength

0.516
  1. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol. 2007 Nov 01; 25(31):4967-73.
    View in: PubMed
    Score: 0.033
  2. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview. J Steroid Biochem Mol Biol. 2003 Sep; 86(3-5):399-403.
    View in: PubMed
    Score: 0.025
  3. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):1007-14.
    View in: PubMed
    Score: 0.024
  4. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist. 2003; 8(4):335-41.
    View in: PubMed
    Score: 0.024
  5. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9.
    View in: PubMed
    Score: 0.023
  6. Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat. 2000 Nov; 64(2):157-63.
    View in: PubMed
    Score: 0.020
  7. Tamoxifen's clinical applications: old and new. Arch Fam Med. 2000 Sep-Oct; 9(9):906-12.
    View in: PubMed
    Score: 0.020
  8. A retrospective study of first indicators of breast cancer recurrence. Oncology. 2000 Apr; 58(3):185-90.
    View in: PubMed
    Score: 0.020
  9. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat. 2016 08; 159(1):109-18.
    View in: PubMed
    Score: 0.015
  10. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15; 77(12):2503-13.
    View in: PubMed
    Score: 0.015
  11. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin. 1995 Jul-Aug; 45(4):199-226.
    View in: PubMed
    Score: 0.014
  12. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol. 1995 Jun; 22(3 Suppl 6):101-4.
    View in: PubMed
    Score: 0.014
  13. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med. 1994 Jan 01; 120(1):18-25.
    View in: PubMed
    Score: 0.013
  14. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol. 1992 Oct; 10(10):1540-6.
    View in: PubMed
    Score: 0.012
  15. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992 Jan 15; 69(2):448-52.
    View in: PubMed
    Score: 0.011
  16. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61.
    View in: PubMed
    Score: 0.011
  17. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast. 2009 Aug; 18 Suppl 2:S1-11.
    View in: PubMed
    Score: 0.009
  18. Recent advances in the hormonal treatment of breast cancer. Curr Probl Surg. 2008 Jan; 45(1):13-55.
    View in: PubMed
    Score: 0.008
  19. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007 May; 18(5):874-80.
    View in: PubMed
    Score: 0.008
  20. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6):1248-54.
    View in: PubMed
    Score: 0.008
  21. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 2006 May 15; 106(10):2095-103.
    View in: PubMed
    Score: 0.007
  22. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006 Mar 01; 24(7):1037-44.
    View in: PubMed
    Score: 0.007
  23. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005 Dec 01; 104(11):2359-64.
    View in: PubMed
    Score: 0.007
  24. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004 Dec 01; 22(23):4691-9.
    View in: PubMed
    Score: 0.007
  25. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5425-31.
    View in: PubMed
    Score: 0.007
  26. Breast carcinoma in men: a population-based study. Cancer. 2004 Jul 01; 101(1):51-7.
    View in: PubMed
    Score: 0.007
  27. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004 Feb 01; 100(3):465-9.
    View in: PubMed
    Score: 0.006
  28. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 2004 Feb 01; 100(3):499-506.
    View in: PubMed
    Score: 0.006
  29. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004 Feb; 4(6):415-9.
    View in: PubMed
    Score: 0.006
  30. Is breast cancer survival improving? Cancer. 2004 Jan 01; 100(1):44-52.
    View in: PubMed
    Score: 0.006
  31. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003 Nov 01; 98(9):1802-10.
    View in: PubMed
    Score: 0.006
  32. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer. 2003 Aug; 39(12):1684-9.
    View in: PubMed
    Score: 0.006
  33. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant. 2003 May; 9(5):330-40.
    View in: PubMed
    Score: 0.006
  34. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer. 2003 Apr 01; 97(7):1758-65.
    View in: PubMed
    Score: 0.006
  35. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003 Mar; 78(1):105-18.
    View in: PubMed
    Score: 0.006
  36. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2002 Oct; 3 Suppl 2:S63-8.
    View in: PubMed
    Score: 0.006
  37. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001 Nov 15; 92(10):2523-8.
    View in: PubMed
    Score: 0.005
  38. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001 Nov 01; 92(9):2247-58.
    View in: PubMed
    Score: 0.005
  39. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001 Oct 01; 92(7):1759-68.
    View in: PubMed
    Score: 0.005
  40. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82.
    View in: PubMed
    Score: 0.005
  41. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001 Feb 01; 19(3):628-33.
    View in: PubMed
    Score: 0.005
  42. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66.
    View in: PubMed
    Score: 0.005
  43. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000 Aug; 18(15):2817-27.
    View in: PubMed
    Score: 0.005
  44. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000 Jul; 7(6):435-40.
    View in: PubMed
    Score: 0.005
  45. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 02; 92(3):225-33.
    View in: PubMed
    Score: 0.005
  46. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat. 1999 Nov; 58(2):157-62.
    View in: PubMed
    Score: 0.005
  47. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999 Mar; 17(3):855-61.
    View in: PubMed
    Score: 0.005
  48. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999 Feb; 17(2):485-93.
    View in: PubMed
    Score: 0.005
  49. High-dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treat Rev. 1998 Aug; 24(4):249-63.
    View in: PubMed
    Score: 0.004
  50. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer. 1998 Jun 15; 82(12):2366-72.
    View in: PubMed
    Score: 0.004
  51. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40(4):321-9.
    View in: PubMed
    Score: 0.004
  52. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996 Apr 22; 156(8):882-8.
    View in: PubMed
    Score: 0.004
  53. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res. 1995 Jul; 1(7):691-7.
    View in: PubMed
    Score: 0.004
  54. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer. 1992 Jan 15; 69(2):476-81.
    View in: PubMed
    Score: 0.003
  55. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol. 1989 Nov; 7(11):1677-84.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.